GNRH1 and uterine corpus leiomyoma: In PRIMROSE 1 and PRIMROSE 2, two parallel, randomized, double-blind, placebo-controlled, phase 3 trials, the efficacy of the GnRH antagonist linzagolix was established with or without ABT (1 mg oestradiol and 0.5 mg norethisterone acetate (NETA)) for reduction of uterine fibroid-related symptoms (Donnez et al., 2022, 2025).